[go: up one dir, main page]

EP2744819A1 - Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl - Google Patents

Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl

Info

Publication number
EP2744819A1
EP2744819A1 EP12747926.9A EP12747926A EP2744819A1 EP 2744819 A1 EP2744819 A1 EP 2744819A1 EP 12747926 A EP12747926 A EP 12747926A EP 2744819 A1 EP2744819 A1 EP 2744819A1
Authority
EP
European Patent Office
Prior art keywords
activity
alkane
acyl
seq
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12747926.9A
Other languages
German (de)
English (en)
Inventor
Steffen Schaffer
Jasmin GIELEN
Nicole Decker
Nicole KIRCHNER
Thomas Haas
Markus PÖTTER
Harald HÄGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Degussa GmbH filed Critical Evonik Degussa GmbH
Publication of EP2744819A1 publication Critical patent/EP2744819A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C12P5/026—Unsaturated compounds, i.e. alkenes, alkynes or allenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T50/00—Aeronautics or air transport
    • Y02T50/60—Efficient propulsion technologies, e.g. for aircraft
    • Y02T50/678—Aviation using fuels of non-fossil origin

Definitions

  • the invention relates to a biotechnological process for the preparation of
  • organic compounds with the aid of at least one alkL gene product.
  • animal fats hardly meet customer acceptance as raw materials as a result of the BSE crisis.
  • Vegetable oils containing short and medium chain fatty acids are either difficult to obtain or produced in tropical regions.
  • the sustainability of production is questioned, as possibly rainforest is cleared to provide the acreage.
  • vegetable and animal oils or fats have specific but definite fatty acid spectra for each raw material. Therefore, a co-production takes place, which can be price-determining for a certain fatty acid species. Last but not least, many of the vegetable oils are at the same time also foodstuffs, so that in certain circumstances there may be competition between recycling and utilization as food.
  • the object of the invention was to provide a biotechnological process for producing organic compounds with a higher productivity.
  • Another object of the invention is the use of the aforementioned microorganisms for the production of organic substances and a process for the production of organic substances using the microorganisms.
  • the invention includes methods for generating recombinant microbial cells capable of producing organic substances such as carboxylic acids and carboxylic acid derivatives such as carboxylic acid esters, alkanes, alkane-1-ols, alkane-1-alkenes, alkane-1-amines, and the like 1 - Alkenes to produce from unrelated carbon sources.
  • the present invention thus comprises a microorganism which has a first genetic modification, so that it is able to form more organic substance from at least one simple carbon source compared to its wild type, characterized in that the microorganism has a second genetic modification such that it forms more alkL gene product compared to its wild type.
  • a first genetic modification is understood to mean at least one genetic modification of the microorganism in which one or more genes have been altered, i.e. increased or reduced in their expression compared to the wild-type strain.
  • simple carbon source in the context of the present invention means carbon sources in which at least one C-C bond broken in the carbon skeleton and / or at least one carbon atom of the simple
  • Carbon source with at least one carbon atom of another molecule must form at least one new bond to get to the carbon skeleton of the "more organic substance formed”.
  • alkL gene product in connection with the present invention means proteins which fulfill at least one of the following two conditions:
  • the protein is recognized as a member of the superfamily of OmpW proteins (3922 protein family in the conserveed Domain Database (CDD) of the National Center for Biotechnology
  • Preferred organic substances of the present invention are those which have more than one, in particular 3 to 36, preferably 6 to 24, in particular 10 to 18
  • the organic substances may be linear, branched, saturated or unsaturated and optionally substituted with other groups. It is preferred according to the invention that the organic substance is selected from the group comprising, preferably consisting of,
  • Carboxylic acids in particular having 3 to 34, preferably having 6 to 22, particularly preferably 6 to 18, carbon atoms,
  • Carboxylic acid esters in particular having 3 to 34, preferably 6 to 22, particularly preferably 6 to 18 carbon atoms in the carboxylic acid moiety, in which the alcohol component is derived from methanol, ethanol or other primary alcohols having 3-18 carbon atoms, in particular of methanol and ethanol .
  • Alkanes having from 3 to 34, preferably from 6 to 22, more preferably from 6 to 18,
  • Alkenes having from 3 to 34, preferably from 6 to 22, more preferably from 6 to 18,
  • monohydric alcohols having from 3 to 34, preferably from 6 to 22, particularly preferably from 6 to 18, carbon atoms,
  • Aldehydes having from 3 to 34, preferably from 6 to 22, more preferably from 6 to 18,
  • monovalent amines having from 3 to 34, preferably from 6 to 22, more preferably from 6 to 18, carbon atoms,
  • esters in the abovementioned compounds are preferably those in which the alcohol component is derived from methanol, ethanol or other primary alcohols having 3-18 carbon atoms, especially methanol and ethanol.
  • the organic substances are selected from fatty acids and
  • Formic acid acetic acid, propionic acid, butyric acid, valeric acid, caproic acid,
  • Pentadecanoic palmitic, margaric, stearic, nonadecanoic
  • Arachidic acid behenic acid, lignoceric acid, cerotic acid, montanic acid, melissinic acid, Undecylenic acid, myristoleic acid, palmitoleic acid, petroselinic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, icosenoic acid, cetoleic acid, erucic acid, nervonic acid,
  • Pelargonic acid linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, calendic acid, punicic acid, ⁇ -elaeostearic acid, ⁇ -elaeostearic acid, arachidonic acid, timnodonic acid, clupanodonic acid, cervonic acid, vernolic acid, ricinoleic acid
  • alkan-1 -alen alkan-1-ols, alkane-1-amines or in the case of unsaturated fatty acids such as palmitoleic, oleic, linoleic, ⁇ -linolenic, ⁇ -linolenic also alkene-1 -alen, alkene-1-ols, alkene-1-amines, produced by enzymatic reduction and decarbonylation of the aforementioned fatty acids
  • alkanoic acids alkan-1-ale, alkan-1-ols or alkan-1-amines are involved directly or indirectly
  • alkanoic acids Alkane-1 -ale, alkane-1-olene or alkane-1-amine. which additionally have one or more, non-terminal, double bonds, are usually included in the specified enzyme activity.
  • carbohydrates such as glucose, sucrose, arabinose, xylose, lactose, fructose, maltose, molasses, starch, cellulose and hemicellulose, but also glycerol or simplest organic molecules such as C0 2 , CO or synthesis gas can be used.
  • microorganisms are used due to the good genetic accessibility; selected from the group of bacteria, especially from the group containing, preferably consisting of,, Magnetococcus, Mariprofundus,
  • Acetobacter Acidiphilium, Afipia, Ahrensia, Asticcacaulis, Aurantimonas, Azorhizobium, Azospirillum, Bartonella, tribocorum, Beijerinckia, Bradyrhizobium, Brevundimonas,
  • Magnetospirillum Maricaulis, Maritimibacter, Mesorhizobium, Methylobacterium, Methylocystis, Methylosinus, Nitrobacter, Novosphingobium, Oceanibulbus, Oceanicaulis, Oceanicola, Ochrobactrum, Octadecabacter, Oligotropha, Paracoccus, Parvibaculum, Parvularcula, Pelagibaca, Phaeobacter, Phenylobacterium, Polymorphum, Pseudovibrio, Rhodobacter, Rhodomicrobium, Rhodopseudomonas, Rhodospirillum, Roseibium, Roseobacter,
  • Agrobacterium Rhizobium, Sinorhizobium, Anaplasma, Ehrlichia, Neorickettsia, Orientia, Rickettsia, Wolbachia, Bordetella, Burkholderia, Cupriavidus, taiwanensis, Lautropia,
  • Desulfococcus Desulfohalobium, Desulfitobacterium, Desulfomicrobium, Desulfonatronospira, Desulfotalea, Desulfovibrio, Desulfuromonas, Geobacter, Haliangium, Hippea, Lawsonia, Myxococcus, Pelobacter, Plesiocystis, Sorangium, Stigmatella, Syntrophobacter, Syntrophus, Arcobacter, Caminibacter, Campylobacter, Helicobacter, Nitratifractor, Nitratiruptor
  • Sulfuricum Sulfurimonas, Sulfurospirillum, Sulfurovum, Wolinella, Buchnera, Blochmannia, Hamiltonella, Regieila, Riesia, Citrobacter, Cronobacter, Dickeya, Edwardsieila, Enterobacter, Erwinia, Escherichia, Klebsiella, Pantoea, Pectobacterium, Proteus, Providencia, Rahnella, Salmonella, Serratia Shigella, Sodalis, Wigglesworthia, Glossina, Xenorhabdus, Yersinia, Acidithiobacillus, Acinetobacter, Aeromonas, Alcanivorax, Alkalimimnicola, Allochromatium, Alteromonadales, Alteromonas, Baumannia, Beggiatoa, Bermanella, Carsonella, Ruthia,
  • Vesicomyosocius Cardiobacterium, Chromohalobacter, Colwellia, Congregibacter, Coxiella, Dichelobacter, Endoriftia, Enhydrobacter, Ferrimonas, Francisella, Glaciecola, Hahella, Halomonas, Halorhodospira, Halothiobacillus, Idiomarina, Kangiella, Legionella, Marinobacter, Marinomonas, Methylobacter, Methylococcus, Methylomicrobium, Methylophaga, Moraxella, Moritella, Neptuniibacter, Nitrococcus, Pseudoalteromonas, Psychrobacter, Psychromona, Reinekea, Rickettsiella, Saccharophagus, Shewanella, Succinatimonas, Teredinibacter, Thioalkalimicrobium, Thioalkalivibrio, Thiomicrospira, Tolumonas,
  • E. coli Pseudomonas sp., Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas stutzeri, Acinetobacter sp., Burkholderia sp., Burkholderia thailandensis, Cyanobacteria, Klebsiella sp., Klebsiella oxytoca, Salmonella sp., Rhizobium sp. and Rhizobium meliloti, with E. coli being particularly preferred.
  • Preferred alkL gene products present in the microorganisms according to the invention are characterized in that the production of the alkL gene product in the native host is induced by dicyclopropyl ketone; In this context it is further preferred that the expression of the alkL gene takes place as part of a group of genes, for example in a regulon such as an operon.
  • AlkL gene products present in the microorganisms according to the invention are preferably encoded by alkL genes from organisms selected from the group of gram-negative bacteria, in particular containing the group, preferably consisting of Pseudomonas sp., Azotobacter sp., Desulfitobacterium sp., Burkholderia sp. , Burkholderia cepacia, Xanthomonas sp., Rhodobacter sp., Ralstonia sp., Delftia sp. and Rickettsia sp., Oceanicaulis sp., Caulobacter sp., Marinobacter sp.
  • Rhodopseudomonas sp. preferably Pseudomonas putida, Oceanicaulis alexandrii, Marinobacter aquaeolei, in particular Pseudomonas putida GPo1 and P1, Oceanicaulis alexandrii HTCC2633, Caulobacter sp. K31 and Marinobacter aquaeolei VT8.
  • alkL gene products are encoded by the alkL genes from Pseudomonas putida GPo1 and P1, which are represented by SEQ ID NO. 1 and SEQ ID NO. 29, as well as proteins with polypeptide sequence SEQ ID NO. 2, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32 or SEQ ID NO. 33 or with a polypeptide sequence of up to 60%, preferably up to 25%, more preferably up to 15%, especially up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid residues SEQ ID NO. 2, SEQ ID NO. 30, SEQ ID NO. 31, SEQ ID NO. 32 or SEQ ID NO.
  • Amount of substance in relation to the amount of cells used (units per gram cell dry weight [U / g CDW]) compared to the activity of the biocatalyst without the presence of the reference protein is understood, in a system as described in the
  • Embodiments will be described in which glucose is converted to palmitoleic acid in an E. coli cell.
  • One method of choice for determining the rate of synthesis is the
  • Biocatalyst converts 1 ⁇ substrate into product in one minute.
  • amino acid residues of a given polypeptide sequence which do not result in significant changes in the properties and function of the given polypeptide are known to those skilled in the art. For example, some amino acids can often be easily exchanged for each other; Examples of such suitable amino acids
  • Amino acid substitutions are: Ala versus Ser; Arg against Lys; Asn versus Gin or His; Asp against Glu; Cys versus Ser; Gin vs Asn; Glu vs Asp; Gly vs Pro; His against Asn or Gin; against Leu or Val; Leu vs Met or Val; Lys versus Arg or Gin or Glu; Mead against Leu or hell; Phe versus Met or Leu or Tyr; Ser against Thr; Thr against Ser; Trp against Tyr; Tyr against Trp or Phe; Val against hell or leu. It is also known that
  • the microorganisms have a first genetic modification so that they are able to form more orgaqnic substance, in particular carboxylic acids and carboxylic acid derivatives, from at least one simple carbon source compared to their wild type.
  • the first genetic engineering modification is an activity of at least one of the enzymes selected from the group, which is increased compared to the enzymatic activity of the wild-type microorganism
  • acyl-ACP acyl carrier protein
  • thioesterase preferably EC 3.1.2.14 or EC 3.1 .2.22, which catalyzes the hydrolysis of an acyl-acyl carrier protein thioester
  • E N acyl-CoA (coenzyme A) thioesterase preferably EC 3.1.2.2, EC 3.1 .2.18, EC 3.1 .2.19, EC 3.1.2.20 or EC 3.1 .2.22, which catalyzes the hydrolysis of an acyl-coenzyme A thioester .
  • Eüb Acyl-CoA (Coenzyme A): ACP (Acyl Carrier Protein) -! "Ransacylase which preferably catalyzes a reaction in which a CoA thioester ACP is converted to a thioester, Ei ,, which catalyzes a reaction polyketide synthase involved in the synthesis of
  • Carboxylic acids and carboxylic acid esters participates, and
  • Hexanoic acid synthase a specialized fatty acid synthase of the FAS-I type, which catalyzes the synthesis of hexanoic acid from 2 molecules of malonyl-coenzyme A and one molecule of acetyl-coenzyme A.
  • Enzymes whose activity can be increased if necessary as well as for increased alkL gene product formation.
  • the term "enhanced activity of an enzyme" as used above and in the following discussion in connection with the present invention is preferably to be understood as an increased intracellular activity and this statement also applies to an increased production of alkL gene product.
  • an increase in enzymatic activity can be achieved by increasing the copy number of the gene sequence or gene sequences which code for the enzyme, using a strong promoter, changing the codon usage of the gene, in various ways the half-life of the mRNA or of the enzyme that increases
  • Genetically modified microorganisms according to the invention are produced for example by transformation, transduction, conjugation or a combination of these methods with a vector which contains the desired gene, an allele of this gene or parts thereof and a promoter which enables the expression of the gene.
  • heterologous expression is achieved by integration of the gene or alleles into the chromosome of the cell or an extrachromosomally replicating vector.
  • the quantification of the increase in enzyme activity can be determined in a simple manner by comparing the 1- or 2-dimensional protein separations between wild-type and genetically modified cell.
  • a common method for preparing the protein gels in bacteria and for identifying the proteins is that of Hermann et al. (Electrophoresis, 22: 1712-23 (2001)
  • the protein concentration can also be determined by Western blot hybridization with an antibody specific for the protein to be detected (Sambrook et al., Molecular Cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY USA, 1989) and subsequent optical evaluation with appropriate software for
  • This method is also always suitable when possible products of the catalyzed by the enzyme activity to be determined reaction in the microorganism quickly
  • Microorganism forms more alkL gene product compared to its wild type.
  • accession numbers cited in connection with the present invention correspond to the ProteinBank database entries of the NCBI dated 26.07.201 1; As a rule, the version number of the entry is identified by ".Ziffer” such as ".1".
  • the reaction catalyzed by E catalyzes the reaction catalyzed by ⁇ l provoke merely by hydrolyzing an acyl-coenzyme A thioester instead of an acyl-acyl carrier protein thioester. It is obvious that many of these enzymes E, will also be used as ⁇ ⁇ due to significant side activity, and vice versa.
  • the enzyme E represents one which comprises sequences selected from:
  • AAC72881.1, ABB71579.1, CAC19934.1, AAC49180.1 encoded by SEQ ID NO: 10
  • AAC72881.1, ABB71579.1, CAC19934.1, AAC49180.1 encoded by SEQ ID NO: 10
  • AEM72521.1 encoded by SEQ ID NO: 35
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E, generally understood in particular the hydrolysis of dodecanoyl-ACP thioester.
  • Microorganisms preferred according to the invention are those which are obtained when the microorganisms listed below having a first genetic modification according to the invention are used as starting point, by being provided with the second genetic engineering modification and optionally at least one further genetic engineering modification according to the invention ,
  • WO2010063031 A2 describes in particular in the sections [0007] to [0008], [0092] to [0100], [0135] to [0136], [0181] to [0186] and [0204] to [0213] as well as US Pat
  • Exemplary embodiments 4 to 8 Microorganisms preferably used according to the invention which have a first genetic engineering modification so that they are able to form more microbial oil from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E according to the invention, and their sequences are described in particular in sections [0012] to [0013], [0155], [0160] to [0163], [0185] to [0190] and [0197] to [0199 ], Figure 12, Embodiments 4 to 8 and Table 3.
  • WO2010063032 A2 describes in particular in the sections [0007] to [0008], [0092] to [0100], [0135] to [0136], [0181] to [0186] and [0204] to [0213] the exemplary embodiments 4 to 8 microorganisms preferably used according to the invention, which have a first genetic modification, so that they are able to form more microbial oil from at least one simple carbon source compared to their wild type.
  • preferred enzymes E and their sequences in particular the
  • WO201 1003034 A2 describes in particular on page 3, second section, to page 7, first section, page 20, second section, to page 22, second section, and on page 156 to page 166, fifth section, and in claims 1 to 100 according to the invention preferably used microorganisms having a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular adipic acid, from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E according to the invention, and their sequences in particular on page 35, third section, and page 36, first section.
  • WO201 1008565 A1 describes, in particular in sections [0018] to [0024] and [0086] to [0102] and exemplary embodiments 2, 4, 7, 9 and 10, microorganisms which are preferably used according to the invention and have a first genetic engineering modification, such that they compared to their wild type more fatty acids and fatty acid derivatives, in particular fatty acids, alkane-1 -ale, alkane-1-ols, alkanes and fatty acid esters, from at least one simple
  • WO2009076559 A1 describes in particular in sections [0013] to [0051] and
  • microorganisms preferably used according to the invention which have a first genetic modification, so that they contain more fatty acids and fatty acid derivatives, in particular fatty acids, alkan-1-ols, alkanes or Alkenes, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences in particular Table 1, sections [0021], [0024] to [0030] and [0064] to [001 11] and FIG. 6.
  • WO2010017245 A1 describes in particular in the sections [001 1] to [0015] and
  • WO2010127318 A2 describes in particular on pages 1 to 9 and 1 to 16, the embodiments 1, 2 and 4, Figures 1A to 1E and claims 23 to 43, 62 to 79 and 101 to 120 according to the invention preferably used microorganisms, which have a first genetic modification, so that they compared to their wild type more fatty acids and fatty acid derivatives, especially biodiesel equivalents and others
  • Fatty acid derivatives especially fatty acid ethyl ester, fatty acid esters, wax esters, alkane-1-ols and alkane-1 -ale, from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E, and their sequences
  • WO2008100251 A1 describes, in particular on pages 4 to 7 and 45 to 46, FIGS. 1A to 1 E and claims 9 to 13, microorganisms which are preferably used according to the invention and have a first genetic modification, so that they contain more fatty acids and Fatty acid derivatives, in particular fatty acid esters, wax esters and alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences in particular pages 4 to 5 and 45 to 46.
  • WO2007136762 A2 describes in particular on pages 2 to 4 and 17 to 18, Table 7, Figures 2 to 4, Embodiments 2 to 8 and Claims 13 and 35 according to the invention preferably used microorganisms containing a first
  • Fatty acids and fatty acid derivatives in particular fatty acid esters, wax esters,
  • Hydrocarbons and alkane-1-ols from at least a simple carbon source assets to make.
  • the document also describes according to the invention preferred enzymes E, and their sequences in particular on pages 17 to 18, in Tables 1, 7, 8 and 10 and the Figure 10.
  • WO20081 13041 A2 describes, in particular, on pages 35 to 41 and 64 to 67, FIG. 2, exemplary embodiments 6 and 10 and claims 7 and 36
  • Microorganisms preferably used according to the invention which have a first genetic engineering modification, so that they contain more fatty acids and
  • Fatty acid derivatives in particular fatty acid esters, wax esters, hydrocarbons, aliphatic ketones and alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in FIG. 7 and the exemplary embodiments 6 and 10.
  • WO2010126891 A1 describes, in particular in sections [0034] to [0091], [0195] to [0222] and [0245] to [0250], FIGS. 3 to 5 and exemplary embodiments 1 to 5, microorganisms preferably used according to the invention have first genetic engineering modification so that they contain more fatty acids and
  • Fatty acid derivatives in particular fatty acid esters, wax esters and alkane-1-ols, from at least one simple carbon source capable of forming.
  • the script also describes
  • WO20101 18410 A1 describes, in particular, in sections [0022] to [0043], [0158] to [0197], FIGS. 1 to 4, exemplary embodiments 3 and 5 to 8 and also US Pat
  • Claims 1 to 53 and 82 to 100 according to the invention preferably used microorganisms having a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular fatty acid esters and wax esters, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E, and their sequences in particular in the
  • WO20101 18409 A1 describes in particular in the sections [0134] to [0154], Figures 1 to 3 and 6 and the embodiment 3 according to the invention preferably used microorganisms having a first genetic modification, so that compared to their wild-type more fatty acids and Fatty acid derivatives, in particular fatty acid esters and wax esters, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in sections [0134] to [0154], FIGS. 3 and 6 and the
  • WO2010075483 A2 describes in particular in the sections [0061] to [0090], and [0287] to [0367], Figures 1, 4 and 5, the embodiments 1 to 38 and claims 18 to 26 microorganisms preferably used according to the invention have a first genetic modification, so they more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular fatty acids, fatty acid methyl esters,
  • Fatty acid ethyl esters alkane-1-ols, fatty alkyl acetates, alkane-1-alkenes, fatty amines, fatty amides,
  • WO2010062480 A2 describes, in particular in sections [0022] to [0174] and [0296] to [0330], exemplary embodiments 3 and 5 to 8 and claims 17 and 24, microorganisms preferably used according to the invention which have a first genetic engineering modification that they have more fatty acids and compared to their wild type
  • Fatty acid derivatives in particular alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention, and their sequences, in particular in the sections [0022] to [0174], Table 1, and the exemplary embodiments 3 and 5 to 8.
  • WO2010042664 A2 describes, in particular in sections [0022] to [0143] and [0241] to [0275], exemplary embodiment 2 and claims 3 and 9, microorganisms preferably used according to the invention which have a first genetic engineering modification, so that they are compared to their wild-type more fatty acids and fatty acid derivatives, in particular alkane-1 -ale, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in Table 1, FIG. 5 and exemplary embodiment 2.
  • WO201 1008535 A1 describes in particular in sections [0024] to [0032], and [0138] to [0158] as well as the figure 13 preferably used according to the invention Microorganisms having a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular carboxylic acids, hydroxy carboxylic acids and their lactones from at least one simple carbon source compared to their wild type.
  • WO2010022090 A1 describes in particular in sections [0022] to [0143] and
  • FIGS. 3 to 5, exemplary embodiment 2 and claims 5, 15, 16 and 36 are microorganisms which are preferably used according to the invention and have a first genetic modification, so that they have more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular fatty acid esters and wax esters, from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E, and their sequences in particular in Table 1, Figure 6 and Embodiment 2.
  • WO2009140695 A1 describes in particular in the sections [0214] to [0248] and the embodiments 22 to 24 microorganisms which are preferably used according to the invention and have a first genetic engineering modification, so that they contain at least .fat. Fatty acids and fatty acid derivatives, in particular hydrocarbons, compared to their wild type be able to form a simple carbon source.
  • the document also describes preferred enzymes E according to the invention, and their sequences in particular in Table 1, Figure 40 and Examples 22 to 24.
  • WO201002171 1 A1 describes in particular in sections [0009] to [0020] and [0257] to [0317], Figures 3 to 5 and 19, the embodiments 2 to 24 and claims 4, 5 and 30 according to the invention preferably used microorganisms which have a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular fatty acid esters and wax esters, from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E according to the invention, and their sequences, in particular in Table 3, Figure 6 and Examples 2 to 24.
  • WO2009085278 A1 describes, in particular in sections [0188] to [0192] and FIG. 10, microorganisms which are preferably used according to the invention and have a first genetic modification, so that they have more properties compared to their wild type
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in Table 1 and FIG. 10.
  • WO201 1019858 A1 describes in particular in the sections [0023], [0064] to [0074] and [0091] to [0099], the embodiments 1 to 13, the Figure 1 and the claim 8 microorganisms preferably used according to the invention, the first have genetic modification so that they contain more fatty acids and
  • Fatty acid derivatives in particular alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in sections [0085] to [0090], den
  • WO2009009391 A2 describes in particular in sections [0010] to [0019] and
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular in sections [0010] to [0019] and [0191] to [0299], FIG. 9 and exemplary embodiments 2, 4 to 6, 9 to 14, 17 and 19th
  • WO2008151 149 A2 describes in particular in sections [0009], [0015] to [0033], [0053], [0071], [0174] to [0191], [0274] and [0396], claims 53 to 1 14, 188 to 206 and 344 to 355 and Tables 1 to 3 according to the invention preferably used
  • Microorganisms that have a first genetic modification, so that they can form more microbial oil from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E according to the invention, and their sequences in particular Table 5.
  • WO2008147781 A2 describes, in particular in sections [0147] to [0156], exemplary embodiments 1 to 3, 8, 9 and 14 and claims 65 to 71, microorganisms which are preferably used according to the invention and have a first genetic engineering modification, so that they are compared to their wild-type more fatty acids and fatty acid derivatives, in particular hydrocarbons, olefins and aliphatic ketones, from at least one simple
  • the WO20081 19082 A2 describes in particular on pages 3 to 5, 8 to 10 and 40 to 77, in Figures 4 and 5, the embodiments 2 to 5 and 8 to 18 and the
  • Microorganisms having a first genetic modification so that they compared to their wild type more fatty acids and fatty acid derivatives, in particular fatty acid esters, wax esters, triglycerides, biodiesel, gasoline, aviation fuel and alkane-1-ols
  • WO2010135624 A2 describes, in particular in sections [0067] to [0083], and [0095] to [0098], microorganisms which are preferably used according to the invention and have a first genetic modification, so that they have more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences in particular in sections [0067] to [0083] and [0095] to [0098].
  • Fatty acids and fatty acid derivatives in particular fatty acid esters, wax esters and alkane-1-ols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences in particular on pages 3807 and in Table 2.
  • Fatty acids and fatty acid derivatives in particular fatty acids and fatty acid esters, from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E, and their sequences, in particular in
  • Lenne RM, Braden DJ, West RA, Dumesic JA and Nursing BF A process for microbial hydrocarbon synthesis: Overproduction of fatty acids in Escherichia coli and catalytic conversion to alkanes., Biotechnol Bioeng., 2010, 106 (2): 193-202) in particular in S.193, first paragraph, p.194, first and second paragraph, p.195, second paragraph to p. 197, second paragraph, p.198, second paragraph to p.
  • microorganisms preferably used according to the invention which have a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular fatty acids and fatty acid esters, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E, and their sequences, in particular on p.193, first paragraph, p.194, first and second paragraph, p.196, second paragraph, and in the Supplementary material.
  • Fatty acids and fatty acid derivatives in particular fatty acids and fatty acid esters, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E according to the invention and their sequences, in particular on page 10639 first paragraph, p. 10640, second, third and last paragraphs, p. 10641, second and third paragraphs, and in Figure 1 and Table 1 and 2.
  • Lu X, Vora H and Khosla C. (Overproduction of free fatty acids in E.coli: implications for biodiesel production., Metab Eng., 2008. 10 (6): 333-9.) Describe in particular in p. 344, second paragraph, Sections 2.2, 2.3 and 3 (first to fourth paragraph) and Table 1 according to the invention preferably used microorganisms having a first genetic modification, so that they compared to their wild type more fatty acids and
  • Fatty acid derivatives in particular fatty acids and fatty acid esters, from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E, and their sequences, in particular in section 2.2.
  • Liu X, Sheng J and Curtiss INI R. (Fatty Acid Production in Genetically Modified Cyanobacteria, Proc Natl Acad Sei USA 201. 1.108 (17): 6899-904) describe in particular on page 6899, fourth and last paragraph, P. 6900, first to penultimate paragraph, and microorganisms preferably used according to the invention in Table S1 of the Supporting Information, which have a first genetic modification, so that they have more fatty acids and fatty acid derivatives, in particular fatty acids and fatty acid esters, compared to their wild-type
  • the document also describes preferred enzymes E according to the invention, and their sequences, in particular on page 6899, sixth and last paragraph.
  • Microorganisms preferred according to the invention are those which are obtained when the microorganisms listed below having a first genetic modification according to the invention are used as starting point, by being provided with the second genetic modification and optionally at least one further genetic engineering modification according to the invention , Steen EJ, Kang Y, Bokinsky G, Hu Z, Schirmer A, McCure A, Del Cardayre SB, and Keasling JD (Microbial production of Fatty-Acid-derived Fuels and Chemicals from Plant Biomass., Nature, 2010. 463 (7280): 559 -62) describe in particular on page 559, third paragraph, to S.559, first Paragraph, microorganisms preferably used according to the invention, which have a first genetic modification, so that they more compared to their wild type
  • Carboxylic acids and carboxylic acid esters in particular fatty acids and fatty acid esters, from at least a simple carbon source assets to make.
  • the document also describes according to the invention preferred enzymes ⁇ ⁇ and their sequences, in particular in
  • Lenne RM, Braden DJ, West RA, Dumesic JA and Nursing BF A process for microbial hydrocarbon synthesis: Overproduction of fatty acids in Escherichia coli and catalytic conversion to alkanes., Biotechnol Bioeng., 2010, 106 (2): 193-202) in particular in S.193, first paragraph, p.194, first and second paragraph, p.195, second paragraph to p. 197, second paragraph, p.198, second paragraph to p.
  • microorganisms preferably used according to the invention which have a first genetic modification, so that they can form more carboxylic acids and carboxylic acid esters, in particular fatty acids and fatty acid esters, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes ⁇ ⁇ and their sequences, in particular on p.193, first paragraph, p.194, first and second paragraph, p.196, second paragraph, and in Supplementary material.
  • Liu T, Vora H and Khosla C. Quantitative analysis and engineering of fatty acid biosynthesis in E. coli. Metab Eng., 2010 Jul; 12 (4): 378-86.
  • Describe in particular in Sections 2.2, and 3.1 and in Table 1 and 2 according to the invention preferably used microorganisms having a first genetic modification, so that they are able to form more carboxylic acids and carboxylic acid esters, in particular fatty acids and fatty acid esters, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes ⁇ ⁇ and their sequences, in particular in Table 1. Yuan L, Voelker TA and Hawkins DJ.
  • Carboxylic acids and carboxylic acid esters in particular fatty acids and fatty acid esters, from at least a simple carbon source assets to make.
  • the document also describes according to the invention preferred enzymes ⁇ ⁇ and their sequences, in particular on p.10639 first paragraph, p. 10640, second, third and last paragraphs, p. 10641, second and third paragraphs, and in Figure 1 and Table 1 and 2.
  • Liu X, Sheng J and Curtiss INI R. (Fatty Acid Production in Genetically Modified Cyanobacteria, Proc Natl Acad Sei USA 201. 1.108 (17): 6899-904) describe in particular on page 6899, fourth and last paragraph, P. 6900, first to penultimate paragraph, and microorganisms preferably used according to the invention in Table S1 of the Supporting Information, which have a first genetic modification such that they contain more carboxylic acids and carboxylic acid esters, especially fatty acids and fatty acid esters, compared to their wild-type
  • the document also describes preferred enzymes ⁇ ⁇ according to the invention and their sequences, in particular on page 6899, sixth and last paragraph.
  • Preferred microorganisms according to the invention are those which are obtained when the microorganisms listed below have a first according to the invention
  • Genetic modification can be used as a starting point by being equipped with the second genetic modification and optionally at least one further genetic engineering modifications in the context of the invention.
  • WO2009121066 A1 describes in particular in claims 8 to 14 according to the invention preferably used microorganisms having a first genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular dicarboxylic acids, from at least one simple carbon source compared to their wild type.
  • the Font also describes according to the invention preferred enzymes Em and their sequences, in particular in the sections [00026] to [0054], the embodiments 1 to 6, Figures 4 to 10 and claims 1 to 7.
  • the WO2009134899 A1 describes in particular in the sections [0079] to [0082], the embodiment 1 and the claim 20 preferably used according to the invention
  • Microorganisms having a first genetic modification so that they are able to form more fatty acids and fatty acid derivatives, in particular carboxylic acids, hydroxy carboxylic acids and their lactones, from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes Em and their sequences according to the invention, in particular in sections [0009] to [0010] and [0044] to [0078], exemplary embodiment 1, FIGS. 1 and 5 to 8 and claims 15 to 17 and 19 ,
  • the enzyme E iv is one which comprises sequences selected from:
  • XP_001241314.1 EGR48038.1, XP_002615278.1, EFW15042.1, EG059647.1, XP_452914.1, XP_962466.1, XP_001537327.1, XP_002796517.1, XP_003305240.1, XP_002543037.1, XP_002499262.1, NP_985412. 2, XP_003019770.1, EFW96269.1, XP_002843350.1,
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E iv generally understood in particular the conversion to hexanoic acid from 2 molecules malonyl coenzyme A and a molecule acetyl coenzyme A.
  • Microorganisms preferred according to the invention are those which are obtained when the microorganisms listed below having a first genetic modification according to the invention are used as starting point, by being provided with the second genetic modification and optionally at least one further genetic engineering modification according to the invention
  • WO201 1003034 A2 describes in particular in p. 2 to 3, p. 5, third section, in the embodiments 1 to 4, 7 to 9 and 12 to 14 and claims 1 to 100 according to the invention preferably used microorganisms having a first genetic modification so they have more fatty acids and compared to their wild type
  • Fatty acid derivatives in particular hexanoic acid from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E iv according to the invention and their sequences on, in particular, page 5 and in exemplary embodiment 3.
  • Fatty acids and fatty acid derivatives in particular hexanoic acid, from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E iv and their sequences in particular p. 299, fourth paragraph, to page 302, first paragraph.
  • Corresponding enzymes E iib are known as acyl-CoA (coenzyme A): ACP (acyl carrier protein) transacylases. Preferred enzymes E iib are selected from
  • EGH97259.1 EGH95622.1, EGH90852.1, EGH85976.1, EGH81248.1, EGH79586.1,
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E iib generally understood in particular the implementation of dodecanoyl-CoA thioester to dodecanoyl-ACP thioester.
  • the microorganism has a third genetic modification that compared one activity enhanced with the enzymatic activity of the wild-type microorganism of at least one of the enzymes E iib, E v , E vi or E vii .
  • this genetic modification is an increased activity of at least one of the enzymes selected from the group compared to the enzymatic activity of the wild-type microorganism
  • Eüb Acyl-CoA (Coenzyme A): ACP (Acyl Carrier Protein) -! "Ransacylase which converts a thioester ACP to a CoA thioester or a CoA thioester in an ACP thioester, E v Sesterheim wax synthase or alcohol O-acyltransferase, preferably of the EC 2.3.1 .75 or EC 2.3. 1 .84, which catalyzes the synthesis of an ester from an acyl-coenzyme A thioester or an ACP thioester and an alcohol,
  • E va fatty acid-O-methyltransferase preferably, the EC 2.1 .1 .15, which catalyzes the synthesis of a Fettklaremethylesters from a fatty acid and S-adenosylmethionine,
  • E vi acyl-CoA (coenzyme A) synthetase preferably EC 6.2.1.3, which catalyzes the synthesis of an acyl-coenzyme A thioester, and
  • E vii acyl thioesterase, preferably EC 3.1.2.2, EC 3.1.2.4, EC 3.1.2.18, EC 3.1 .2.19, EC 3.1 .2.20 or EC 3.1 .2.22, which comprises reacting an acyl thioester with an alcohol Carboxylic acid esters catalyzed.
  • the third genetic modification selects combinations of the enhanced activities of the enzymes
  • Preferred enzymes E iib in connection with the third genetic modification correspond to the above-mentioned preferred enzymes E iib in connection with the first genetic modification.
  • the enzyme E v represents one comprising sequences selected from:
  • NP_808414.2 NP_001178653.1, XP_003272721.1, XP_002720111.1, NP_001002254.1, XP_529027.1, XP_002831804.1, BAC28882.1, XP_549056.2, XP_002918053.1,
  • ZP_08461736.1, ZP_08461735.1, ZP_07608690.1, YP_045555.1 encoded by SEQ ID NO: 19
  • YP_004427559.1 YP_001277083.1, YP_001276783.1, YP_524767.1, YP_522739.1, YP_521788.1, YP_004335162.1, YP_004333708.1, YP_004332973.1, YP_004332349.1,
  • ZP_05528769.1 ZP_05527907.1 ZP_05227984.1, ZP_05227897.1, ZP_05227653.1
  • ⁇ 09102.1 in particular ⁇ _045555.1 (encoded by SEQ ID NO: 19), YP_694462.1 (encoded by SEQ ID NO: 67) and NP_808414.2.
  • Biocatalyst is understood without the presence of the reference protein, wherein under the
  • E v Activity in this context and in connection with the determination of the activity of the enzyme E v generally understood in particular the conversion of dodecanoyl-CoA thioester and / or dodecanoyl-ACP thioester with methanol to dodecanoyl methyl ester. If the enzyme E v is an alcohol O-acyltransferase of EC 2.3.1.84, it is preferred that these are selected from:
  • EGA72844.1 NP_015022.1, S69991, AAP72991.1, EDN63695.1, BAA05552.1, AAP72992.1, S69992, AAP72995.1, XP_002552712.1, XP_001646876.1, XP_002551954.1, EGA82692.1, EDN61766. 1, EGA86689.1, EGA74966.1, AAU09735.1, NP_01 1693.1, XP_445666.1,
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E v is generally understood in particular the conversion of dodecanoyl-CoA thioester with methanol to dodecanoyl methyl ester.
  • Microorganisms preferred according to the invention are those which are obtained when the microorganisms listed below having a third genetic modification according to the invention are used as a starting point, by having a first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO2007136762 A2 describes in particular on pages 2 to 4 and 21 to 24, Figures 2 to 4, the embodiments 1, 2 and 5 to 7 and the claims 1, 2, 5, 6, 9 to 27 and 33 according to the invention preferably used Microorganisms that have a third genetic modification, so they more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular fatty acid esters, wax esters,
  • Hydrocarbons and alkane-1-ols from at least a simple carbon source assets to make.
  • the document also describes according to the invention preferred enzymes E v and their sequences, in particular on pages 21 to 24, in Table 10 and Figure 10.
  • the enzyme E va is one which comprises sequences selected from YP_001851637.1 (encoded by SEQ ID NO: 14) as well as proteins having a polypeptide sequence of up to 60%, preferably up to 25%, especially preferably up to 15%, in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid residues relative to the aforementioned reference sequence are altered by deletion, insertion, substitution or a combination thereof and which are still at least 50%, preferably 65%, more preferably 80%, in particular more than 90% of the activity of the protein with the corresponding above-mentioned reference sequence, wherein below 100% activity of the reference protein, the increase in the activity of the cells used as a biocatalyst, ie the amount of substance reacted per unit time based on the amount of cell used (units per gram
  • the enzyme E vi represents one which comprises sequences selected from YP_001724804.1 (encoded by SEQ ID NO: 18)
  • Proteins having a polypeptide sequence at up to 60%, preferably up to 25%, more preferably up to 15%, in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid residues compared to aforementioned reference sequence are altered by deletion, insertion, substitution or a combination thereof and which still have at least 50%, preferably 65%, more preferably 80%, in particular more than 90% of the activity of the protein with the corresponding aforementioned reference sequence, wherein below 100 % Activity of the reference protein, the increase in the activity of the cells used as biocatalyst, ie the amount of substance reacted per unit time, based on the amount of cell used (units per gram
  • Cell dry weight [U / g CDW]) is understood in comparison to the activity of the biocatalyst without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E vi in general in particular the synthesis of Dodecanoyl-CoA thioester is understood.
  • Microorganisms preferred according to the invention are those which are obtained when the microorganisms listed below having a third genetic modification according to the invention are used as a starting point, by having a first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO2010075483 A2 describes, in particular in sections [0061] to [0090] and [0287] to [0367], FIGS. 1, 4 and 5, exemplary embodiments 1 to 38 and claims 18 to 26, microorganisms preferably used in accordance with the invention have third genetic modification, so they more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular fatty acids, fatty acid methyl esters,
  • alkan-1-ols, alkan-1 -alen, alkan-1-amines and olefins it may be advantageous to aminate the corresponding carboxylic acids or esters, correspondingly reduce enzymatically to decarboxylate or to
  • preferred microorganisms according to the invention have a fourth genetic modification which, compared with the enzymatic activity of the wild-type
  • Microorganism enhanced activity includes at least one of the selected from the group Eüb Acyl-CoA (Coenzyme A): ACP (Acyl Carrier Protein) -! "Ransacylase which converts a thioester ACP to a CoA thioester or a CoA thioester in an ACP thioester, E vi acyl-CoA (coenzyme A) synthetase, preferably of the EC 6.2.1.3 which the synthesis of an acyl Coenzyme A thioester catalyzes,
  • Eviü acyl-CoA (coenzyme A) reductase preferably the EC 1 .2.1 .42 or EC 1 .2.1.50, which preferably the reduction of an acyl-coenzyme A thioester to the corresponding alkane-1-al or alkane-1 - ol catalyzes,
  • E ix fatty acid reductase also fatty aldehyde dehydrogenase or aryl aldehyde oxidoreductase
  • EC 1 .2.1.3, EC 1 .2.1.20 or EC 1.2.1 .48 which preferably the reduction of an alkanoic acid to the corresponding alkane-1-al catalyzed
  • E x acyl-ACP (acyl carrier protein) reductase preferably EC 1 .2.1.80, which catalyzes the reduction of an acyl-ACP thioester to the corresponding alkan-1-al or alkan-1-ol,
  • E xi cytochrome P450 fatty acid decarboxylase which catalyzes the reaction of an alkanoic acid having n carbon atoms into a corresponding terminal olefin having n-1 carbon atoms, in particular from dodecanoic acid to undec-10-enoic acid,
  • the fourth genetic modification selects combinations of increased activities of the enzymes selected from
  • Preferred enzymes E iib in connection with the fourth genetic modification correspond to the above-mentioned preferred enzymes in connection with the
  • Preferred enzymes E vi in connection with the fourth genetic modification correspond to the enzymes E vi mentioned above as being preferred in connection with the third genetic modification.
  • Microorganisms which are preferred according to the invention are those which are obtained when the microorganisms listed below having a fourth genetic modification according to the invention are used as a starting point, comprising first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO201 1008565 A1 describes, in particular in sections [0021], [0103] to [0106], [0108] and [0129], microorganisms preferably used according to the invention which have a fourth genetic modification, so that they have more compared to their wild type
  • Fatty acids and fatty acid derivatives in particular fatty acids, fatty aldehydes, fatty alcohols, alkanes and fatty acid esters from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E vii i and their sequences in particular the sections [0104] to [0106] as well as [0108] and [0129] and the
  • Embodiment 1 1.
  • WO2008151 149 A2 describes in particular in sections [0009], [0015] to [0037], [0053], [0071], [0171], [0174] to [0191], [0274] and [0396] Claims 53 to 1 14, 188 to 206 and 344 to 355 and Tables 1 to 3 according to the invention preferably used microorganisms having a fourth genetic modification, so that they are able to form more microbial oil from at least one simple carbon source compared to their wild type.
  • the document also describes the present invention preferred enzymes vii E i and their sequences in particular paragraphs [0255] to [0261] and [0269] as well as Tables 6 and 7.
  • WO2007136762 A2 describes in particular on pages 2 to 4 and 19 to 20, Figures 2 to 4, the embodiments 2 to 7 and the claims 4, 8 to 27 and 33 according to the invention preferably used microorganisms having a fourth genetic modification, so that they have more fatty acids and compared to their wild type Fatty acid derivatives, in particular fatty acid esters, wax esters, hydrocarbons and
  • Fatty alcohols capable of forming at least one simple carbon source.
  • the document also describes according to the invention preferred enzymes E vii i and their sequences, in particular on pages 19 to 20, in Table 10 and Figure 10.
  • WO201 1019858 A1 describes in particular in the sections [0015] to [0020], [0064] to [0074], [0085] to [0086] and [0092] to [0099], the embodiments 1 to 13, of Figure 1 and claims 1 to 14 according to the invention preferably used
  • Microorganisms which have a fourth genetic modification, so that they can form more fatty acids and fatty acid derivatives, in particular fatty alcohols, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E vii i and their sequences, in particular in the
  • WO2009140695 A1 describes in particular in the sections [0031] to [0040], [0051] and [0214] to [0233] , the embodiments 5 to 24 and 28 to 30, Table 1, Figure 40, and claims 29 to 30 according to the invention preferably used
  • Microorganisms which have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular hydrocarbons, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E vii i and their sequences, in particular in sections [0023] to [0030], [0056], [0066] to [0069] and [0193] to [0208], Table 1, the Figure 39, the embodiments 5 to 24 and 28 to 30 and the claims 69 to 74.
  • WO201 1008535 A1 describes in particular in the sections [0023] to [0024], and [0133] to [0158], the Figure 13, the claims 39 and 45 to 47 and the
  • Exemplary embodiments 1 to 5 microorganisms preferably used according to the invention which have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular carboxylic acids, hydroxy carboxylic acids and their lactones, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E vii i and their sequences, in particular in sections [0017] to [0022], [0084] to [0132], Figures 2 to 12, claims 31 to 37 and 40 to 44 and Exemplary embodiments 1 to 5.
  • WO2010063031 A2 describes in particular in sections [0007], [0092] to [0100], [0181] to [0183] and [0199] to [0213] preferably used according to the invention
  • Microorganisms having a fourth genetic modification so that they can form more microbial oil from at least one simple carbon source compared to their wild type.
  • the document also describes the present invention preferred enzymes E vii i and their sequences in particular paragraphs [0191] to [0194] and Tables 4 and 5.
  • the WO2010063032 A2 describes, in particular in paragraphs [0007], [0092] to [0100], [0181] to [0183] and [0199] to [0213] are preferably used according to the invention
  • Microorganisms having a fourth genetic modification so that they can form more microbial oil from at least one simple carbon source compared to their wild type.
  • the document also describes the present invention preferred enzymes vii E i and their sequences in particular paragraphs [0191] to [0194] and Tables 4 and 5.
  • the enzyme E ix represents one which comprises sequences selected from YP_887275.1 (encoded by SEQ ID NO: 17), ABI83656.1 (encoded by SEQ ID NO: 122), and
  • Proteins having a polypeptide sequence at up to 60%, preferably up to 25%, more preferably up to 15%, in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid residues compared to abovementioned reference sequences are modified by deletion, insertion, substitution or a combination thereof and which still have at least 50%, preferably 65%, particularly preferably 80%, in particular more than 90%, of the activity of the protein with the corresponding above-mentioned reference sequence, whereby below 100 % Activity of the reference protein is the increase in the activity of the cells used as biocatalyst, ie the amount of substance reacted per unit time, based on the amount of cells used (units per gram of cell dry weight [U / g CDW]) compared to the activity of
  • the synthesis of lauryl aldehyde, NADP, AMP and 2 P, from lauric acid, ATP, NADPH and H + is generally understood to mean biocatalyst without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E ix is understood.
  • Microorganisms which are preferred according to the invention are those which are obtained when the microorganisms listed below having a fourth genetic modification according to the invention are used as a starting point, comprising first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO201 1019858 A1 describes, in particular, in sections [0004] to [0008], [0064] to [0074], [0085] to [0086], [0095] to [0099], exemplary embodiments 1 to 13 of FIG and claim 7 microorganisms preferably used according to the invention which have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular fatty alcohols, from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E ix according to the invention and their sequences, in particular in sections [0008] to
  • WO2010135624 A2 describes, in particular in sections [0005], [0067] to [0085] and [0092] to [0102], claims 13 to 17 and embodiments 1 to 4, microorganisms which are preferably used according to the invention and have a fourth genetic engineering modification so they have more fatty acids and compared to their wild type
  • Fatty acid derivatives in particular carboxylic acids, hydroxy-carboxylic acids and their lactones from at least one simple carbon source capable of forming.
  • the document also describes according to the invention preferred enzymes E ix and their sequences, in particular in the
  • WO2010062480 A2 describes in particular in the sections [0022] to [0174] and [0292] to [0316], the embodiments 1 and 3 to 8, the illustration 9 and the
  • the document also describes preferred enzymes E ix according to the invention and their sequences, in particular in sections [0019] to [0032] and
  • WO201042664 A2 describes, in particular in sections [0236] to [0261], exemplary embodiment 2, FIGS. 1 and 5 and claim 25, microorganisms which are preferably used according to the invention and have a fourth genetic modification, so that they have more fatty acids compared to their wild type and fatty acid derivatives, in particular fatty alcohols, from at least one simple carbon source capable of forming.
  • the document also describes preferred enzymes E ix according to the invention and their sequences, in particular in sections [021 1] to [0233], FIGS. 2 to 4 and exemplary embodiments 1 to 2.
  • the enzyme E x is one which comprises sequences selected from BAB85476.1 (encoded by SEQ ID NO: 77), YP_047869.1 (encoded by SEQ ID NOS 79 and 81, respectively), YP_959486.1 ( encoded by SEQ ID NO: 83), YP_959769.1 (encoded by SEQ ID NO: 139), B9TSP7.1 (encoded by (SEQ ID NO: 141), and
  • Proteins having a polypeptide sequence at up to 60%, preferably up to 25%, more preferably up to 15%, in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid residues compared to abovementioned reference sequences are modified by deletion, insertion, substitution or a combination thereof and which still have at least 50%, preferably 65%, particularly preferably 80%, in particular more than 90%, of the activity of the protein with the corresponding above-mentioned reference sequence, whereby below 100 % Activity of the reference protein is the increase in the activity of the cells used as biocatalyst, ie the amount of substance reacted per unit time, based on the amount of cells used (units per gram of cell dry weight [U / g CDW]) compared to the activity of
  • Microorganisms which are preferred according to the invention are those which are obtained when the microorganisms listed below have a fourth according to the invention
  • Genetic modification can be used as a starting point by being equipped with a first and second genetic modification and optionally at least one further genetic engineering modifications within the meaning of the invention.
  • WO2007136762 A2 describes in particular on pages 2 to 4 and 19 to 20, Figures 2 to 4, the embodiments 2 to 7 and the claims 4, 8 to 27 and 33 according to the invention preferably used microorganisms having a fourth genetic modification, so that they have more fatty acids and compared to their wild type
  • Fatty acid derivatives in particular fatty acid esters, wax esters, hydrocarbons and
  • Fatty alcohols capable of forming at least one simple carbon source.
  • the document also describes preferred enzymes E x according to the invention and their sequences, in particular on pages 19 to 20, in Table 10 and in FIG. 10.
  • WO201 1019858 A1 describes in particular in the sections [0015] to [0020], [0064] to [0074], [0085] to [0086] and [0092] to [0099], the embodiments 1 to 13, of Figure 1 and claims 1 to 14 according to the invention preferably used
  • Microorganisms which have a fourth genetic modification, so that they can form more fatty acids and fatty acid derivatives, in particular fatty alcohols, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E x and their sequences, in particular in the
  • WO2009140695 A1 describes in particular in the sections [0031] to [0040], [0051] and [0214] to [0233] , Embodiments 5 to 24 and 28 to 30, Table 1, Figure 40, and claims 29 to 30 according to the invention preferably used microorganisms having a fourth genetic modification, so that compared to their wild-type more fatty acids and fatty acid derivatives, in particular hydrocarbons to be able to form from at least one simple carbon source.
  • WO201 1008535 A1 describes in particular in the sections [0023] to [0024], and [0133] to [0158], the Figure 13, the claims 39 and 45 to 47 and the
  • Exemplary embodiments 1 to 5 microorganisms preferably used according to the invention have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular carboxylic acids, hydroxy carboxylic acids and their lactones from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E x according to the invention and their sequences, in particular in sections [0017] to [0022], [0084] to [0132], FIGS. 2 to 12, claims 31 to 37 and 40 to 44 and the exemplary embodiments 1 to 5.
  • the enzyme E xi represents one which comprises sequences selected from ADW41779.1 (encoded by SEQ ID NO. 168) as well as
  • Pentadecene, C0 2 and water is understood.
  • Microorganisms which are preferred according to the invention are those which are obtained when the microorganisms listed below having a fourth genetic modification according to the invention are used as a starting point, comprising first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO2009085278 A1 describes in particular in sections [0033] to [0048], [0056] to [0063] and [0188] to [0202], FIG. 10, Table 8, exemplary embodiments 5 to 18 and claims 28 to 51 and 188 to 195 according to the invention preferred
  • Microorganisms which have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular olefins, from at least one simple carbon source compared to their wild type.
  • the document also describes according to the invention preferred enzymes E xi and their sequences, in particular in the
  • Microorganisms which are preferred according to the invention are those which are obtained when the microorganisms listed below having a fourth genetic modification according to the invention are used as a starting point, comprising first and second genetic modification and optionally at least one further genetic engineering modification according to the invention be equipped.
  • WO2009140695 A1 describes in particular in sections [0031] to [0040], [0051] and [0214] to [0233], exemplary embodiments 5 to 24 and 28 to 30, table 1, figure 40, and claims 29 to 30 preferred according to the invention
  • Microorganisms which have a fourth genetic modification, so that they are able to form more fatty acids and fatty acid derivatives, in particular hydrocarbons, from at least one simple carbon source compared to their wild type.
  • the document also describes preferred enzymes E xii according to the invention and their sequences, in particular in sections [0023] to [0030], [0056], [0066] to [0069] and [0193] to [0208], Table 1, of the Figure 38, the embodiments 5 to 24 and 28 to 30 and the claims 69 to 74.
  • WO2008151 149 A2 describes in particular in sections [0009], [0015] to [0037], [0053], [0071], [0171], [0174] to [0191], [0274] and [0396] Claims 53 to 1 14, 188 to 206 and 344 to 355 and Tables 1 to 3 according to the invention preferred
  • Microorganisms having a fourth genetic modification such that they have more microbial oil from at least one simple carbon source compared to their wild type make money.
  • the document also describes preferred enzymes E xii according to the invention and their sequences in particular Table 8.
  • the enzyme E xii i is preferably an ⁇ -transaminase of the EC 2.6.1.-.
  • Preferred enzymes E xii i are selected from the group:
  • EGE58369.1 EGH06681.1, EGH08331.1, EGH24301.1, EGH32343.1, EGH46412.1,
  • NP_901695.1 encoded by Seq ID No. 132
  • YP_353455.1 preferably NP_901695.1 (encoded by Seq ID No. 132), YP_353455.1, as well as
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E xii i in general in particular the reaction of co-oxo-lauric acid and / or co-oxo-lauric acid methyl ester to ⁇ -amino Lauric acid and / or co-amino-lauric acid methyl ester is understood.
  • the enzyme E xiv is an amino acid dehydrogenase, such as serine dehydrogenases, aspartate dehydrogenases, phenylalanine dehydrogenases and glutamate dehydrogenases, more preferably an alanine dehydrogenase of EC 1.4.1.1.
  • Such preferred alanine dehydrogenases are selected from
  • YP_004087624.1 ADP99134.1, YP_003590847.1, YP_003589189.1, YP_001192379.1, ZP_08473868.1, ZP_08469833.1, ZP_08462614.1, ZP_07709417.1, ZP_07672507.1, ZP_07608107.1, ZP_07404685.1, ZP_07334010.
  • ⁇ _08263846.1 ⁇ _07898723.1, ⁇ _003273311.1, ⁇ _05909597.1, ⁇ _003073095.1, ⁇ _003022905.1, ⁇ _003013384.1, ⁇ _003011072.1, ⁇ _04777180.1, ⁇ _04432601.1, ⁇ _001016505.1, ⁇ _953175.1, ⁇ _731492. 1, ⁇ _08302086.1, ⁇ _08296718.1,
  • ⁇ _002634404.1 ⁇ _439119.1, ⁇ _314402.1, YPJ43482.1, ⁇ _295618.1, ⁇ _08215173.1, ⁇ _004282846.1, ⁇ _004267961.1, ⁇ _001867313.1, ⁇ _001301882.1, ⁇ _847214.1, ⁇ _004095847.1, ⁇ _003338282. 1, ⁇ _003337256.1, ⁇ _355846.1, ⁇ _253131.1,
  • ZP_07970379.1 ZP_07962751.1, ZP_07953732.1, ZP_07945354.1, ZP_06273519.1,
  • ZP. _03916440 1 ZP. , 03703407 1 ZP. , 03675960 1 ZP. , 03588177 1 ZP. , 03569636.1
  • ⁇ _04689103.1 ⁇ _04658071.1, ⁇ _002364705.1, ACN89388.1, 2VHW_A, 2VHV_A, ⁇ _001324625.1, ⁇ 06259.1, ABR57171.1, CAO90307.1, CAM75354.1, CAA44791.1, ⁇ 77513.1, EGR96638. 1, EGR94699.1, ⁇ _08693646.1, ⁇ _004740306.1,
  • ⁇ _003326349.1 ⁇ _003289755.1, ⁇ _003089327.1, ⁇ _07911965.1, ⁇ _05773583.1, ⁇ _05765271.1, ⁇ _003154888.1, ⁇ _003142045.1, ⁇ _002280953.1, ⁇ _371963.1, ⁇ _422368.1, EGC98966.1, EGC76398. 1, ⁇ _004263661.1, ⁇ _004252039.1, ⁇ _679036.1, ⁇ _499973.1, ⁇ _08090745.1, ⁇ _08108339.1, ⁇ _001531594.1, ⁇ _01051588.1,
  • ZP_04170954.1 YP_002453687.1, ZP_04153266.1, ZP_04302850.1, YP_002365390.1, ZP_04216141.1, ZP_04298961 .1, ZP_00740055.1, ZP_04277177.1, ZP_04104350.1, ZP_04176651.1, YP_001647239.1, ZP_04188247.
  • Biocatalyst is understood without the presence of the reference protein, in a system in which pyruvate is converted to alanine.
  • microorganisms are preferred which are a fifth
  • acyl-CoA synthetase preferably EC 6.2.1.3, which catalyzes the synthesis of an acyl-coenzyme A thioester
  • E b acyl-CoA dehydrogenase preferably EC 1.3.99.-, EC 1.3.99.3, or EC 1 .3.99.13, which catalyzes the oxidation of an acyl-coenzyme A thioester to the corresponding enoyl coenzyme A thioester,
  • E c acyl CoA oxidase preferably EC 1.3.3.6, which catalyzes the oxidation of an acyl coenzyme A thioester to the corresponding enoyl coenzyme A thioester,
  • E d enoyl-CoA hydratase preferably EC 4.2.1.17 or EC 4.2.1.74, which catalyzes the hydration of an enoyl coenzyme A thioester to the corresponding 3-hydroxyacyl coenzyme A thioester,
  • E e 3-hydroxyacyl-CoA dehydrogenase preferably of EC 1.1.1.35, or EC 1 .1 .1.21 1, which catalyzes the oxidation of a 3-hydroxyacyl coenzyme A thioester to give the corresponding 3- oxoacyl-Coenzyme A thioesters and
  • E f acetyl-CoA acyltransferase preferably EC 2.3.1.16, which catalyzes the transfer of an acetyl residue from a 3-oxoacyl-coenzyme A thioester to coenzyme A and thus produces an acyl-coenzyme A thioester shortened by two carbon atoms .
  • Modification, but also by the second, third and fourth genetic modification increasingly formed carboxylic acids and carboxylic acid derivatives is prevented.
  • reduced activity compared to its wild-type is preferably reduced by at least 50%, more preferably by at least 90%, more preferably by at least 99.9%, even more preferably by at least 99.99% and most
  • decreased activity also does not include a detectable activity ("zero activity") .
  • the reduction of the activity of a particular enzyme may be achieved, for example, by targeted mutation or by other, Further methods for reducing enzymatic activities in microorganisms are known to the person skilled in the art, in particular molecular biology techniques are available here Instructions for the modification and reduction of protein expressions and thus
  • Microorganisms preferred according to the invention are characterized in that the reduction of the enzymatic activity is achieved by modification of a gene comprising a nucleic acid sequence coding for the abovementioned enzymes, wherein the
  • Modification is selected from the group comprising, preferably consisting of, insertion of foreign DNA into the gene, deletion of at least parts of the gene, point mutations in the gene sequence, RNA interference (siRNA), antisense RNA or modification (insertion, deletion or Point mutations) of regulatory sequences flanking the gene.
  • siRNA RNA interference
  • antisense RNA modification (insertion, deletion or Point mutations) of regulatory sequences flanking the gene.
  • foreign DNA is to be understood as meaning any DNA sequence which is "foreign" to the gene (and not to the organism)
  • the gene is interrupted by insertion of a selection marker gene, thus the foreign
  • the selection marker gene is extended by further functionalities, which in turn make possible a subsequent removal from the gene. This can be achieved, for example, by the Organism foreign recombination systems, such as a Cre / loxP system or FRT ⁇ Flippase Recognition 7argei) system or the organism's own homologous recombination system.
  • the reduction of the activity of the microorganism according to the invention in comparison to its wild-type is determined by the method described above for determining the activity using cell numbers / concentrations that are as similar as possible, the cells being grown under the same conditions as, for example, medium, gassing, agitation.
  • the enzyme E a represents one which comprises the sequence NP_416319.1 (SEQ ID NO: 18)
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E a is generally understood in particular the synthesis of dodecanoyl-CoA thioester.
  • the enzyme E b represents one which comprises sequences selected from: YP_488518.1 (coded by Seq ID No. 14, formerly AP_000876.1), ZP_08341828.1,
  • YP_004434754.1 YP_662062.1, YP_004068195.1, ZP_08409704.1, ZP_08622396.1, ZP_01135962.1, ZP_03560927.1, ZP_04716612.1, EGB41427.1, EGP48304.1, EFV84045.1, ZP_08505249.1, ZP_06688896.
  • EFW81359.1 EGH83675.1, EGH67821.1, EFW83732.1, ⁇ _273865.1, ⁇ _06457469.1, EGH99235.1, ⁇ _03397893.1, ⁇ _07004262.1, ⁇ _07263971.1, EGH75297.1, EGH31566.1, EGH45251.
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E b is generally understood in particular the oxidation of dodecanoyl-CoA thioester to 2-dodecenoyl-CoA thioester.
  • the enzyme E c is one which comprises sequences selected from: YP_003571780.1, YP_445820.1, ⁇ _634556.1, ⁇ _004665862.1, ⁇ _01461690.1,
  • ⁇ _04691466.1 ⁇ _001109453.1, ⁇ _08240125.1, ⁇ _003272226.1, ⁇ _004053469.1, ⁇ _06272176.1, ⁇ _004491616.1, ⁇ _001133991.1, ⁇ _001071715.1, ⁇ _290295.1, ⁇ _003193744.1, ⁇ _001704317.1, ⁇ _004008413. 1, ⁇ _004655806.1, ⁇ _640598.1, ⁇ _08153802.1, ⁇ _00995173.1, ⁇ _05225674.1, ⁇ _888747.1, ⁇ _003114111.1,
  • ⁇ _04691466.1 ⁇ _001109453.1, ⁇ _08240125.1, ⁇ _003272226.1, ⁇ _004053469.1, ⁇ _06272176.1, ⁇ _004491616.1, ⁇ _001133991.1, ⁇ _001071715.1, ⁇ _290295.1, YP_003193744.1, YP_001704317.1, ⁇ _004008413.1, ⁇ _004655806.1, ⁇ _640598.1, ⁇ _08153802.1, ⁇ _00995173.1, ⁇ _05225674.1, ⁇ _888747.1, ⁇ _0031 141 1 1 .1,
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E c is generally understood in particular the oxidation of dodecanoyl-CoA thioester to 2-dodecenoyl-CoA thioester.
  • Particular Enzymes E d and E e Furthermore, it is preferred according to the invention that in the cells according to the invention the enzyme E d or E e is one which comprises sequences selected from:
  • ⁇ _001881164.1 ⁇ _003655512.1, ⁇ _002237269.1, ⁇ _004116642.1, ⁇ _03065203.1, ⁇ _07951118.1, CAQ79951.1, ⁇ 26206.1, ⁇ 12062.1, ⁇ _269853.2, ⁇ _930429.2, ⁇ _404102.1, ⁇ _04620204. 1, ⁇ _08498986.1, ⁇ _001452041.1, ⁇ _01159981.1,
  • YP_004107339.1 YP_001203133.1, ZP_01546752.1, YP_002974094.1, ZP_02186892.1, YP_001989920.1, YP_002964466.1, ZP_03265887.1, YP_555553.1, CBA26305.1,
  • ZP_03070699.1 ZP_07145404.1, ZP_08376058.1, EGB85466.1, ZP_07189176.1,
  • Biocatalyst is understood without the presence of the reference protein, wherein the activity in this context and in connection with the determination of the activity of the enzyme E d and E e generally in particular the conversion of 2-dodecenoyl-CoA thioester to 3-oxo-dodecanoyl-CoA -Thiester is understood.
  • Particular Enzymes E f Furthermore, it is preferred according to the invention that in the cells according to the invention the enzyme E f represents one which comprises sequences selected from:
  • YP_003208639.1 3GOA_A, YP_003739634.1, ZP_06192593.1, YP_001906199.1
  • YP_001476498.1 YP_003019596.1, YP_003261566.1, ZP_03831341.1, ZP_07380062.1, YP_048334.1, YP_003933022.1, ZP_07953301.1, YP_004114075.1, YP_002647269.1, ADP11111.1, ZP_03827988.1, ZP_06638308.
  • YP_004214865.1 YP_003518495.1
  • YP_002989324.1 ZP_01236909.1, ZP_01161146.1, ZP_08310904.1, YP_003713992.1, YP_003466461.1, NP_931576.1, YP_003042703.1, ZP_06050959.1, EGF42157.1, ZP_00992844.1, YP_002415748.1, ZP_01065522.1, ZP_05883432.1, ZP_05879948.1, ZP_06156528.1, ZP_05927570.1, ZP_07189177.1, YP_004564871.1, ZP_01870126.1, ZP_02196042.1, YP_003911299.1, ZP_01815882. 1, NP_796408.1, YP_004394587.1,
  • NP_759945.1 YP_001143923.1, NP_932821.1, Q5E8X7.2, ZP_08568928.1, ZP_06078671.1, ZP_05718021.1, ZP_01948567.1, YP_203407.3, ZP_04923725.1, ZP_05719937.1,
  • ZP_03805050.1 YP_004468426.1, ZP_03841336.1, YP_002153225.1, YP_004425807.1, ZP_03351120.1, YP_659788.1, YP_004436298.1, YP_267150.1, ZP_06034790.1,
  • ZP_03360083.1 YP_574438.1, YP_003073152.1, YP_001083375.1, ZP_08648989.1, YP_001982171.1, ZP_05096741.1, ZP_03336985.1, ZP_01103277.1, ZP_07136312.1, ZP_08328590.1, ZP_05128805.1, EGH76239. 1, ZP_03377529.1, CBA71811.1, EFZ47010.1, ZP_03377530.1, ZP_07136311.1, EFZ47009.1, EGH29725.1, YP_003022611.1,
  • YP_002138248.1 ZP_01462439.1, ZP_06499584.1, YP_004669687.1, YP_633289.1, ZP_01907074.1, YP_001611010.1, ADI22030.1, ZP_03026937.1, YP_580525.1,
  • ZP_06188204.1 ABF82237.1, ZP_06016043.1, YP_046135.1, YP_942111.1, ZP_01614052.1, YP_001341942.1, YP_004713534.1, ZP_01460231.1, YP_001630800.1, YP_001264278.1, CAD76924.1, ZP_07200324. 1, YP_550745.1, YP_001413963.1, YP_002132758.1,
  • ⁇ _004473788.1 EGH77345.1, ⁇ 45363.1, EGH44350.1, ⁇ _001676522.1, ⁇ _05824514.1, ⁇ _06487592.1, ⁇ _02887415.1, ⁇ _04761513.1, ⁇ _003377502.1, ⁇ _001188713.1, ⁇ _01167911.1, ⁇ _06690267.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé biotechnologique de production de composés organiques au moyen d'au moins un produit génique alkL.
EP12747926.9A 2011-08-15 2012-08-15 Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl Withdrawn EP2744819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011110945A DE102011110945A1 (de) 2011-08-15 2011-08-15 Biotechnologisches Syntheseverfahren von organischen Verbindungen mit alkIL-Genprodukt
PCT/EP2012/065933 WO2013024111A1 (fr) 2011-08-15 2012-08-15 Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl

Publications (1)

Publication Number Publication Date
EP2744819A1 true EP2744819A1 (fr) 2014-06-25

Family

ID=46679271

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12747926.9A Withdrawn EP2744819A1 (fr) 2011-08-15 2012-08-15 Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl

Country Status (6)

Country Link
US (1) US20140186905A1 (fr)
EP (1) EP2744819A1 (fr)
CN (1) CN103987727A (fr)
DE (1) DE102011110945A1 (fr)
SG (2) SG2014010615A (fr)
WO (1) WO2013024111A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010043470A1 (de) 2010-11-05 2012-05-10 Evonik Degussa Gmbh Zusammensetzung aus Polyamiden mit niedriger Konzentration an Carbonsäureamidgruppen und elektrisch leitfähigem Kohlenstoff
DE102010043473A1 (de) 2010-11-05 2012-05-10 Evonik Degussa Gmbh Carbon Nanotubes enthaltende Polyamid 12-Zusammensetzung
UA112980C2 (uk) 2011-02-16 2016-11-25 Евонік Дегусса Гмбх Рідкі катіоніти
DE102011084521A1 (de) 2011-10-14 2013-04-18 Evonik Industries Ag Verwendung einer Mehrschichtfolie mit Polyamid- und Polypropylenschichten für die Herstellung photovoltaischer Module
EP2602328A1 (fr) 2011-12-05 2013-06-12 Evonik Industries AG Procédé d'oxydation d'alcanes en utilisant d'une alcane 1-mono-oxygénase AlkB
EP2607479A1 (fr) 2011-12-22 2013-06-26 Evonik Industries AG Production bio-technologique d'alcools et dérivés associés
EP2607490A1 (fr) 2011-12-22 2013-06-26 Evonik Industries AG Procédé de séparation améliorée d'une solution organique hydrophobe et d'un milieu de culture aqueux
EP2631298A1 (fr) 2012-02-22 2013-08-28 Evonik Industries AG Procédé biotechnologique et procédé de production de butanol et d'acide butyrique
EP2639308A1 (fr) 2012-03-12 2013-09-18 Evonik Industries AG Omega-oxydation et -amination enzymatique d'acides gras
DE102012204181A1 (de) 2012-03-16 2013-09-19 Evonik Degussa Gmbh Elektrisch leitfähigen Kohlenstoff enthaltende Polyamidzusammensetzung
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2647696A1 (fr) 2012-04-02 2013-10-09 Evonik Degussa GmbH Procédé de fabrication aérobie d'alanine ou d'une liaison établie sous consommation d'alanine
DE102012207921A1 (de) * 2012-05-11 2013-11-14 Evonik Industries Ag Mehrstufiges Syntheseverfahren mit Synthesegas
EP2700448A1 (fr) 2012-08-21 2014-02-26 Evonik Industries AG Acides gras ramifiés comme échangeurs de cations liquides
EP2706076B1 (fr) 2012-09-07 2014-12-17 Evonik Industries AG Compositions durcissables à base de résines époxy sans alcool benzylique
EP2730655A1 (fr) 2012-11-12 2014-05-14 Evonik Industries AG Procédé de conversion d'un ester d'acide carboxylique en utilisant des cellules déficientes en BioH
EP2746400A1 (fr) 2012-12-21 2014-06-25 Evonik Industries AG Fabrication d'amines et de diamines à partir d'acide carbonique ou d'acide de dicarbone ou un mono-ester composé de ceux-ci
EP2746397A1 (fr) 2012-12-21 2014-06-25 Evonik Industries AG Fabrication d'acides gras oméga-aminés
EP2759598A1 (fr) 2013-01-24 2014-07-30 Evonik Industries AG Procédé de fabrication d'alpha, oméga-alcane-diol
EP2944696A1 (fr) 2014-05-13 2015-11-18 Evonik Degussa GmbH Procédé de production de composés organiques
EP2944697A1 (fr) 2014-05-13 2015-11-18 Evonik Degussa GmbH Procédé de production de nylon
WO2015176020A1 (fr) 2014-05-16 2015-11-19 Provivi, Inc. Synthèse d'alcools oléfiniques par l'intermédiaire de l'hydroxylation terminale enzymatique
CN105624179A (zh) * 2014-11-18 2016-06-01 中国科学院青岛生物能源与过程研究所 一种生产脂肪端烯的系统及其应用
CA2937594A1 (fr) * 2015-02-26 2016-08-26 Evonik Degussa Gmbh Production d'alkene
WO2017102952A1 (fr) 2015-12-17 2017-06-22 Evonik Degussa Gmbh Cellule acétogène génétiquement modifiée
WO2018019867A1 (fr) 2016-07-27 2018-02-01 Evonik Degussa Gmbh N-acétyl homosérine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301993A (fr) 1962-12-18
NL8700085A (nl) * 1987-01-15 1988-08-01 Rijksuniversiteit Werkwijze voor het bereiden van verbindingen met eindstandige hydroxyl- of epoxygroep; daarvoor bruikbare microorganismen.
US5254466A (en) 1989-11-06 1993-10-19 Henkel Research Corporation Site-specific modification of the candida tropicals genome
US5298421A (en) * 1990-04-26 1994-03-29 Calgene, Inc. Plant medium-chain-preferring acyl-ACP thioesterases and related methods
DE10031999A1 (de) 1999-09-09 2001-04-19 Degussa Verfahren zur fermentativen Herstellung von D-Pantothensäure unter Verwendung coryneformer Bakterien
EP1506302A4 (fr) 2002-05-23 2006-02-08 Cognis Ip Man Gmbh Candida tropicalis bloque par oxydation beta non reversible
WO2008100251A1 (fr) 2007-02-13 2008-08-21 Ls9, Inc. Microorganisme modifie et son utilisation
JP5933909B2 (ja) 2006-05-19 2016-06-15 アールイージー ライフ サイエンシズ リミテッド ライアビリティ カンパニー 脂肪酸およびその誘導体の生産
WO2008113041A2 (fr) 2007-03-14 2008-09-18 Ls9, Inc. Procédé de production d'hydrocarbures de bas poids moléculaire à partir de ressources renouvelables
CA3178593A1 (fr) 2007-03-28 2008-10-02 Genomatica, Inc. Production amelioree de derives d'acides gras
BRPI0813359A2 (pt) 2007-05-22 2014-10-14 Ls9 Inc Ácidos nucleicos isolados, vetor, células, métodos para produzir um hidrocarboneto, para produzir uma cetona alifática, para produzir um polipeptídeo purificado, para produzir um hidrocarboneto, para produzir biocombustíveis, hidrocarboneto, biocombustível, polipeptídeo isolado, ácido nucleico isolado, organismos geneticamente engenheirados, método para identificar uma enzima útil para a produção de hidrocarbonetos
JP2010528627A (ja) 2007-06-01 2010-08-26 ソラザイム、インク 微生物による油の生産
WO2009009391A2 (fr) 2007-07-06 2009-01-15 Ls9, Inc. Systèmes et procédés pour la production d'esters gras
BRPI0821508B1 (pt) 2007-12-11 2018-12-26 Synthetic Genomics Inc cultura celular compreendendo uma cianobactéria recombinante da espécie synechococcus elongatus e método para converter carbono inorgânico em ácidos graxos.
US8183028B2 (en) 2007-12-21 2012-05-22 Ls9, Inc. Methods and compositions for producing olefins
CN102015995B (zh) 2008-03-03 2014-10-22 焦耳无限科技公司 产生碳基目的产物的二氧化碳固定工程微生物
WO2009121066A1 (fr) 2008-03-28 2009-10-01 The Regents Of The University Of California Production d’acides dicarboxyliques utilisant des polycétide synthases
CN102014623A (zh) 2008-04-29 2011-04-13 加利福尼亚大学董事会 使用聚酮化物合酶制备生物燃料
MX2010012192A (es) 2008-05-16 2011-04-26 Ls9 Inc Metodos y composiciones para producir hidrocarburos.
US20100071259A1 (en) 2008-08-18 2010-03-25 Ls9, Inc. Systems and methods for production of mixed fatty esters
MX2011003597A (es) 2008-10-07 2011-06-20 Ls9 Inc Metodos y composiciones para producir aldehidos grasos.
EP2796559B1 (fr) 2008-10-28 2018-09-12 REG Life Sciences, LLC Cellule microbienne pour la production d'alcools gras
ES2583639T3 (es) 2008-11-28 2016-09-21 Terravia Holdings, Inc. Producción de aceites específicos en microorganismos heterótrofos
CN110129296A (zh) 2008-12-23 2019-08-16 Reg生命科学有限责任公司 硫酯酶相关的方法和组合物
CN102459569B (zh) 2009-04-10 2018-02-23 Reg生命科学有限责任公司 脂肪酸衍生物的产生
WO2010118410A1 (fr) 2009-04-10 2010-10-14 Ls9, Inc. Production de dérivés d'acide gras
CN102459622B (zh) 2009-04-27 2020-08-18 基因组股份公司 脂肪酸酯的产生
EP2424989A2 (fr) 2009-05-01 2012-03-07 The Regents of The University of California Produit d'esters d'acide gras à partir de polymères de biomasse
WO2010135624A2 (fr) 2009-05-22 2010-11-25 Codexis, Inc. Biosynthèse modifiée d'alcools gras
WO2011008565A1 (fr) 2009-06-29 2011-01-20 Synthetic Genomics, Inc. Gènes d'acyl-acp thiostérase et leurs utilisations
BRPI1013277A2 (pt) 2009-06-30 2016-10-11 Codexis Inc produção de alcoóis graxos a partir de células hospedeiras recombinantes e seus usos
SG176970A1 (en) 2009-07-02 2012-02-28 Verdezyne Inc Biological methods for preparing adipic acid
EP2464722B1 (fr) 2009-08-11 2017-10-04 Synthetic Genomics, Inc. Production microbienne d'alcools gras
DE102010015807A1 (de) * 2010-04-20 2011-10-20 Evonik Degussa Gmbh Biokatalytisches Oxidationsverfahren mit alkL-Genprodukt

Also Published As

Publication number Publication date
US20140186905A1 (en) 2014-07-03
WO2013024111A1 (fr) 2013-02-21
SG10201606683PA (en) 2016-10-28
DE102011110945A1 (de) 2013-02-21
CN103987727A (zh) 2014-08-13
SG2014010615A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
EP2744819A1 (fr) Procédé biotechnologique de synthèse de composés organiques au moyen d'un produit génique alkl
AU2020294235B2 (en) Methods of producing omega-hydroxylated fatty acid derivatives
EP2744897A2 (fr) Procédé biotechnologique de synthèse d'acides carboxyliques fonctionnalisés en oméga et esters d'acides carboxyliques à base de sources de carbone simples
DE102010015807A1 (de) Biokatalytisches Oxidationsverfahren mit alkL-Genprodukt
BR112014015077A2 (pt) método para produzir um alcano di- ou trifuncional
EP3038595A1 (fr) Procédé de production d'acides acyl aminés
US20230167419A1 (en) Omega-Hydroxylase-Related Fusion Polypeptides With Improved Properties
EP3020819A1 (fr) Acide gras et production de dérivés
US12180515B2 (en) Omega-hydroxylase-related fusion polypeptide variants with improved properties
JP7186261B2 (ja) ω－官能化カルボン酸及びそのエステルの生物工学的な製造
US9487804B2 (en) Hydroxy- and dicarboxylic-fat synthsis by microbes
배진형 Development of a Novel Escherichia coli Host Strain for Long-chain Fatty Acid Hydroxylation
HK1210226A1 (en) Preparation of amines and diamines from a carboxylic acid or dicarboxylic acid or a monoester thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1195565

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170315

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1195565

Country of ref document: HK